{"id":"W2151822189","doi":"10.1093/rheumatology/keh153","title":"Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate","year":2004,"lang":"en","type":"review","venue":"Lara D. Veeken","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"McMaster University; University of Ottawa; Abbott Laboratories","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Placebo; Infliximab; Internal medicine; Methotrexate; Population; Physical therapy; Health Utilities Index; Quality of life (healthcare); TNF inhibitor; Quality-adjusted life year; Surgery; Health related quality of life; Cost effectiveness; Tumor necrosis factor alpha; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008258455,0.001096437,0.004382352,0.000666349,0.0003315301,0.0001499355,0.0003937907,0.0003605972,0.0002278011],"category_scores_gemma":[0.00004707492,0.0007732661,0.0004031658,0.0009400496,0.0004830186,0.0003013939,0.0001469356,0.001298432,0.00003431929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008912688,"about_ca_system_score_gemma":0.001956754,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006672737,"about_ca_topic_score_gemma":0.001860041,"domain_scores_codex":[0.9937113,0.0005368153,0.001660334,0.001311026,0.001318098,0.001462425],"domain_scores_gemma":[0.9969728,0.00009577395,0.0008560603,0.001099175,0.0002674221,0.0007087767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000642865,0.001543781,0.0488942,0.01482836,0.001288396,0.0007052524,0.0003339436,0.000004909284,0.000002870298,0.0001057819,0.00007284046,0.9315768],"study_design_scores_gemma":[0.05533284,0.01297715,0.117311,0.3671834,0.0001429418,0.0003895509,0.0001692861,0.00004242343,0.00003452246,0.0001153353,0.4434797,0.002821819],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1510707,0.8433123,0.00004068949,0.0000455146,0.00004970094,0.004703126,0.00035642,0.0001595094,0.0002619973],"genre_scores_gemma":[0.04380081,0.9516951,0.0004900284,0.00004615381,0.00003792219,0.0004007116,0.003210795,0.0002072958,0.0001111838],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.928755,"threshold_uncertainty_score":0.9999419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02429936411162434,"score_gpt":0.3230364257934593,"score_spread":0.2987370616818349,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}